Compare GCMG & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCMG | BWAY |
|---|---|---|
| Founded | 1971 | 2003 |
| Country | United States | Israel |
| Employees | 553 | 129 |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.0M | 674.2M |
| IPO Year | N/A | N/A |
| Metric | GCMG | BWAY |
|---|---|---|
| Price | $10.56 | $15.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $14.33 | $13.25 |
| AVG Volume (30 Days) | ★ 323.9K | 139.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.28 | $309.69 |
| Revenue Next Year | $11.70 | $26.21 |
| P/E Ratio | ★ $28.21 | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.30 | $10.01 |
| 52 Week High | $13.22 | $26.63 |
| Indicator | GCMG | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 43.04 |
| Support Level | $10.35 | $14.56 |
| Resistance Level | $11.84 | $16.63 |
| Average True Range (ATR) | 0.41 | 0.62 |
| MACD | -0.09 | -0.20 |
| Stochastic Oscillator | 20.44 | 21.03 |
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG, and absolute return strategies. The company invests maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.